B · Normal
[Sanofi’s new generation rabies vaccine VaxRabeo has been approved by the EU and is suitable for all ages] On November 19th, Sanofi announced that the European Commission has approved the new generation rabies vaccine VaxRabeo for rabies pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) for people of all ages. This is the first time VaxRabeo has received marketing authorization, after the European Medicines Agency's Committee for Medicinal Products for Human Use passed a positive opinion on September 17. Sanofi said that the vaccine is produced using Vero cell technology and has a longer shelf life and better thermal stability than existing rabies vaccines. The shelf life is 60 months and can remain stable at a maximum temperature of 27°C for 96 hours before reconstitution. Clinical studies have shown that the vaccine has protective antibody levels comparable to existing vaccines in pre-exposure prophylaxis and has similar immunogenicity characteristics in post-exposure prophylaxis.
Global market intelligence 🕐 2026-11-19 14:07

Related telegraphs

Comments

0/500
Captcha (click to refresh)
No comments yet